Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 9, 2010, Pages 662-664

  Arnolds, S ^a   Rave, K ^a   Hovelmann U ^a   Fischer, A ^a   Sert Langeron, C ^b   Heise, T ^a  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b SANOFI   (France)

Author keywords

insulin aspart; insulin glulisine; pharmacodynamics; pharmacokinetics

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLULISINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INFUSION RATE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADSORPTION; ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEALTH; HUMAN EXPERIMENTATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 77958144693     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1252067     Document Type: Article

References (12)

1. Simpson D, McCormack PL, Keating GM, et al. Insulin lispro. A review of its use in the management of diabetes mellitus. Drugs 2007 67 (3) 407-434
2. 1. Summary of Product Characteristics (SPC), May 2007. Available from URL: http//www.fachinfo.de (Accessed 2008 Oct 08)
3. Chapman TM, Noble S, Goa KL. Insulin aspart. A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002 62 (13) 1945-1981
4. 1. Summary of Product Characteristics (SPC), August 2007. Available from URL: http//www.fachinfo.de. (Accessed 2008 Oct 08)
5. Becker RHA, Frick AD, Nosek L, Heinemann L, Rave K. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care 2007 30 2506-2507
6. Becker RHA, Frick AD, Burger F, et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005 113 435-443
7. Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabet Obes Metab 2007 9 746-753
8. Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 2007 9 109-121
9. Bolli GB, Luzio S, Porcellati F, et al. Pharmacodynamic and pharmacokinetik effects of subcutaneous insulin glulisine versus insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetologia 2009 52 968
10. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005 37 702-707
11. Hanefeld M, Fischer S, Julius U, et al. The DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996 39 1577-1583
12. Chiasson JL, Josse RG, Gomis R, et al. for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA 2003 290 486-494